Manipal Health Enterprises, which operates the Manipal Hospitals network, made its initial public offering (IPO) public yesterday. The issue has attracted a lot of attention as one of India’s largest healthcare IPOs, but this may have played out in the grey market premium (GMP) before the opening, which is likely to be more modest than expected.
The IPO will remain open for subscription from July 29 to July 31, 2026. This time the company has set a price band of ₹560–₹590 per equity share and investors can bid within this range. This public issue consists of the fresh issue and an Offer for Sale (OFS) by existing shareholders, taking the total issue size to ₹9,275 crore.
Manipal Health raised ₹4,167 crore from anchor investors in the run-up to the IPO, and attracted some of the major institutional investors. The strong anchor book is indicative of confidence in the hospital chain’s long-term growth prospects, under downward pressure on grey market sentiment.
The latest GMP has dropped to around ₹2 per share, suggesting that the new issue will only fetch a little extra value than the issue price. A lower GMP simply indicates cautious sentiment in the unofficial market even if it does not mean the stock will perform well in the stock market. A lot of the time, investors consult the company's underlying business rather than what they see on the grey market.
Manipal Health Enterprises is one of India's leading private healthcare providers with a large network of multi-specialty hospitals in the country. The company has been expanding aggressively in recent years through acquisitions, growing its presence in key healthcare markets and gaining more patients.
A lot of the fresh issue funds will be used for debt, to clean up the balance sheet and to fund future expansion plans, and most of that for the new IPO according to the company’s IPO documents. Analysts say reducing leverage can help the company, and will allow for better long-term growth.
The brokerages remain divided on the issue. And while many see long-term potential in India’s rapidly growing healthcare industry and Manipal Hospitals’ strong brand, some say that the IPO is priced at a premium, and investors need to consider the valuation carefully before purchasing shares.
The subscription response from QIBs, non-institutional investors (NIIs) and retail individual investors (RIIs) over the next three days will be closely watched too. Strong demand from different investor categories could also have a bearing on the market mood before the company's imminent listing.
As one of the largest healthcare IPOs of the year, Manipal Hospitals' public issue is expected to be the focus during the subscription period. Investors will keep an eye on subscription figures, GMP movement and institutional participation in order to make their investment decisions.
Comments
Please to leave a comment on this article.